17 September 2020 - Gilead withdrew its request for the reimbursement of remdesivir in France on 31 August 2020.

The opinion is in favour of reimbursement only in the management of patients aged 12 years or over and weighing at least 40 kg, hospitalised for COVID-19 with pneumonia requiring low flow oxygen therapy and at dosages in the marketing authorisation.

The actual benefit (SMR) of remdesivir was rated by the Transparency Commission as low.

Read Transparency Commission opinion for remdesivir [French]